453 results on '"Takimoto, Chris"'
Search Results
52. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion
53. Anticancer drug development at the US National Cancer Institute
54. Contributors
55. Non-Clinical Drug Development
56. Utilizing Pharmacokinetics/Pharmacodynamics Modeling to Simultaneously Examine Free CCL2, Total CCL2 and Carlumab (CNTO 888) Concentration Time Data
57. A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients
58. Clinical Trials in Special Populations
59. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan
60. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion
61. Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer.
62. Pharmacokinetic (PK)-pharamcodynamic (PD) analysis and receptor occupancy data to support every other week maintenance dosing of magrolimab in combination with azacitidine in MDS/AML patients.
63. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
64. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
65. A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
66. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
67. Contributors
68. Preclinical Drug Development
69. Personalized Medicine in Oncology Drug Development
70. An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
71. Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab
72. The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
73. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates
74. Thymidylate synthase inhibitors
75. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
76. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?
77. Camptothecins
78. Design, Conduct, and Interpretation of Organ Impairment Studies in Oncology Patients
79. Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer
80. Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function
81. Can docetaxel dosing be individualized based on cytochrome p450 activity?
82. Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors
83. Dose-Intense Paclitaxel: Déjà Vu All Over Again?
84. Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study
85. Epidermal Growth Factor Receptor and Other Molecular Targets in the Treatment of Cancer
86. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study
87. A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies
88. Chapter 1 - Changing Landscape of Early Phase Clinical Trials: Beyond the Horizon
89. The Multifunctional, Multi-Institutional, and Sometimes Even Global Phase I Study: A Better Life for Phase I Evaluations or Just “Living Large”?
90. Phase I & pharmacokinetic study of LY231514 (pemetrexed disodium, MTA) in renal dysfunction patients (pts)
91. Phase I trail of a Human-EngineeredTM monoclonal anti-EpCAM antibody, ING-1(heMAb), in patients (pts) with advanced adenocarcinomas
92. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro
93. Commentary on “Thymidylate Synthase Pharmacogenetics in Colorectal Cancer”
94. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
95. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
96. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
97. Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors
98. Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients
99. The Clinical Development of 9-Aminocamptothecin
100. Improving attribution of adverse events in oncology clinical trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.